88 related articles for article (PubMed ID: 9450614)
1. In vivo homologous regulation of mu-opioid receptor gene expression in the mouse.
Sehba F; Duttaroy A; Shah S; Chen B; Carroll J; Yoburn BC
Eur J Pharmacol; 1997 Nov; 339(1):33-41. PubMed ID: 9450614
[TBL] [Abstract][Full Text] [Related]
2. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
Duttaroy A; Yoburn BC
Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
[TBL] [Abstract][Full Text] [Related]
3. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
4. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
[TBL] [Abstract][Full Text] [Related]
5. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
Stafford K; Gomes AB; Shen J; Yoburn BC
Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
[TBL] [Abstract][Full Text] [Related]
6. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
7. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
Patel MB; Patel CN; Rajashekara V; Yoburn BC
Mol Pharmacol; 2002 Dec; 62(6):1464-70. PubMed ID: 12435815
[TBL] [Abstract][Full Text] [Related]
8. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
[TBL] [Abstract][Full Text] [Related]
9. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
Zhang Q; Purohit V; Yoburn BC
Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
[TBL] [Abstract][Full Text] [Related]
10. Opioid receptor regulation in mice.
Yoburn BC; Billings B; Duttaroy A
J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
[TBL] [Abstract][Full Text] [Related]
11. Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
Gomes BA; Shen J; Stafford K; Patel M; Yoburn BC
Pharmacol Biochem Behav; 2002 May; 72(1-2):273-8. PubMed ID: 11900797
[TBL] [Abstract][Full Text] [Related]
12. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
[TBL] [Abstract][Full Text] [Related]
13. Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells.
Crain SM; Shen KF
Brain Res; 1996 Nov; 741(1-2):275-83. PubMed ID: 9001733
[TBL] [Abstract][Full Text] [Related]
14. Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.
Madia PA; Dighe SV; Sirohi S; Walker EA; Yoburn BC
Psychopharmacology (Berl); 2009 Dec; 207(3):413-22. PubMed ID: 19816677
[TBL] [Abstract][Full Text] [Related]
15. [(35)S]GTPĪ³S binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
16. Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus.
Van Bockstaele EJ; Commons KG
Neuroscience; 2001; 108(3):467-77. PubMed ID: 11738260
[TBL] [Abstract][Full Text] [Related]
17. The effect of intrinsic efficacy on opioid tolerance.
Duttaroy A; Yoburn BC
Anesthesiology; 1995 May; 82(5):1226-36. PubMed ID: 7741298
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude.
Allen RM; Dykstra LA
J Pharmacol Exp Ther; 2000 Dec; 295(3):1012-21. PubMed ID: 11082436
[TBL] [Abstract][Full Text] [Related]
19. Agonist-specific down regulation of mu-opioid receptors: Different cellular pathways are activated by different opioid agonists.
Binyaminy B; Gafni M; Shapira M; Sarne Y
Life Sci; 2008 Apr; 82(15-16):831-9. PubMed ID: 18358497
[TBL] [Abstract][Full Text] [Related]
20. Etorphine increases the number of mu-opioid receptor-positive cells in the cerebral cortex.
Melone M; Brecha NC; Sternini C; Evans C; Conti F
Neuroscience; 2000; 100(3):439-43. PubMed ID: 11098106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
